


Supporting Information:


Table 1. Chemical properties of the PEG-*b*-PPLG copolymers

PEG m.w.	Side group	M.W. (g/mol)	DP _n	Dispersity ^a	Yield(%)	Identification
5 kDa	Diisopropyl	15,200	53	1.15	64	1
	Diethyl	14,300	53	1.11	70	2
10 kDa	Diisopropyl	21,200	45	1.12	76	3
	Diethyl	20,200	45	1.13	68	4

^a<http://pac.iupac.org/publications/pac/pdf/2009/pdf/8102x0351.pdf>



S1a



S1b

Figure S1a: Cryo-TEM image of vesicles formed from copolymer **2**. S1b: Particle size analysis by DLS in PBS at room temperature (r.t.) and at 37 °C.




Figure S2: Organ-wise distribution of the block copolymer **1** vesicle at donor and FRET channel.




Figure S3: (Left) % injected dose (ID) recovered via fluorescence following retro-orbital bleeding for copolymer **1** vesicles. (Right) FRET efficiency of isolated blood, complementing the circulation profile, quantifying radiant efficiency of fluorescence recovery in donor and FRET channel and calculating the efficiency as the ratio of the total FRET radiant efficiency to the sum total of that in the FRET and donor channel for copolymer **1** vesicles.




Figure S4. Tumor growth prior to treatment with the doxorubicin-loaded PEG-*b*-PPLG system